Autoimmune hepatitis and liver transplantation: Indications, results, and management of recurrent disease

Seminars in Liver Disease

Volumn 29, Issue 3, 2009, Pages 286-296

  Tripathi, Dhiraj ^a   Neuberger, James ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Autoimmune hepatitis; De novo autoimmune hepatitis; Liver transplantation; Recurrence

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISOLONE; RAPAMYCIN; SORAFENIB; STEROID; TACROLIMUS; THALIDOMIDE;

AUTOIMMUNE HEPATITIS; COLITIS; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER BIOPSY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; POSTTRANSPLANTAT LIVER DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SURVIVAL TIME; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME;

DISEASE PROGRESSION; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PATIENT SELECTION; RECURRENCE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 68849085114     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1233531     Document Type: Review

References (86)

1. Verslype C, George C, Buchel E, Nevens F, van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005; 21(6):695-699
2. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5): 929-938
3. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18(4):998-1005
4. Hennes EM, Zeniya M, Czaja AJ, et al; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1): 169-176
5. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41(1):207-215
6. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51(5):968-975
7. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45(4):584-591
8. Alvarez F, Ciocca M, Cañero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30(2):222-227
9. Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006;43(5):635-639
10. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371-375
11. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103(12):3063-3070
12. Kanzler S, Gerken G, Dienes HP, Meyer zum Büschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997;35(7):571-578
13. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008;21(5):459-465
14. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33(2):464-470
15. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31(4):864-871
16. Neuberger J, Gimson A, Davies M, et al; Liver Advisory GroupUK Blood and Transplant. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008;57(2):252-257
17. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1): 25-34
18. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390
19. Polak WG, Soyama A, Slooff MJ. Liver transplantation in patients with hepatocellular carcinoma. Ann Transplant 2008; 13(4):5-15
20. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693-699
21. Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48(3):819-827
22. Mazzaferro V, Llovet JM, Miceli R, et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10(1):35-43
23. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimusbased immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007;83(9):1162-1168
24. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97(2):439-445
25. Ichai P, Duclos-Vallée JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13(7): 996-1003
26. Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 1989;11(3):303-307
27. Bosch J, Coll M, Puig A, et al. Autoimmune hepatitis with fatal outcome. J Pediatr 1991;118(5):823-824
28. Ferrari R, Pappas G, Agostinelli D, et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM 2004;97(7): 407-412
29. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997;27(3):578-582
30. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2(7):625-631
31. Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990;116(2):280-282
32. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21(5):866-871
33. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25(3):263-270
34. Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998;17(3):297-300
35. Villamil AG, Casciato P, Eduardo M, et al. Fulminant autoimmune hepatitis: Clinical presentation, outcome and prognostic factors. Am J Transplant 2005;5:278
36. Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS Liver Transplant Registry. Clin Transpl 2004:315-329
37. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002;8(6):519-526
38. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998;29(1):143-150
39. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984;37(4):363-365
40. Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 2000;32(2):185-192
41. Bahar RJ, Yanni GS, Martín MG, et al. Orthotopic liver transplantation for autoimmune hepatitis and cryptogenic chronic hepatitis in children. Transplantation 2001;72(5): 829-833
42. Birnbaum AH, Benkov KJ, Pittman NS, McFarlane-Ferreira Y, Rosh JR, LeLeiko NS. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997;25(1):20-25
43. Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008; 14(9):1281-1286
44. Duclos-Vallée JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893-897
45. González-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7(4):302-310
46. Heffron TG, Smallwood GA, Oakley B, et al. Autoimmune hepatitis following liver transplantation: relationship to recurrent disease and steroid weaning. Transplant Proc 2002; 34(8):3311-3312
47. Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc 2007;39(4):1166-1170
48. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68(2):253-256
49. Narumi S, Hakamada K, Sasaki M, et al. Liver transplantation for autoimmune hepatitis: rejection and recurrence. Transplant Proc 1999;31(5):1955-1956
50. Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998;66(12):1645-1650
51. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999;30(1):131-141
52. Reich DJ, Fiel I, Guarrera JV, et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000;32(4 Pt 1):693-700
53. Renz JF, Ascher NL. Liver transplantation for nonviral, nonmalignant diseases: problem of recurrence. World J Surg 2002;26(2):247-256
54. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18(1):62-69
55. Wright HL, Bou-Abboud CF, Hassanein T, et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992;53(1):136-139
56. Yusoff IF, House AK, De Boer WB, et al. Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol 2002;17(2):203-207
57. Kerkar N, Hadzić N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351(9100): 409-413
58. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12(12):1813-1824
59. Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases. World J Gastroenterol 2008;14(21): 3388-3395
60. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self. Hepatology 2000;32(4 Pt 1):868-870
61. Hübscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 2001;7(4):285-291
62. Evans HM, Kelly DA, McKiernan PJ, Hübscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006;43(5):1109-1117
63. Junge G, Neuhaus R, Schewior L, et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005;37(4):1695-1696
64. Uemura T, Ikegami T, Sanchez EQ, et al. Late acute rejection after liver transplantation impacts patient survival. Clin Transplant 2008;22(3):316-323
65. Devlin J, Donaldson P, Portmann B, Heaton N, Tan KC, Williams R. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl Surg 1995;1(3):162-165
66. Milkiewicz P, Ahmed M, Hathaway M, Elias E. Factors associated with progression of the disease before transplantation in patients with autoimmune hepatitis. Liver 1999;19(1):50-54
67. Hurtova M, Duclos-Vallée JC, Johanet C, et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl 2001;7(6):556-558
68. Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005;5(5):1085-1089
69. Rodríguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant Proc 2006;38(5):1467-1470
70. Seyam M, Neuberger JM, Gunson BK, Hübscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl 2007;13(7): 966-974
71. Di Cocco P, Barletta A, Clemente K, et al. De novo autoimmune hepatitis following liver transplantation: a case report. Transplant Proc 2008;40(6):2073-2074
72. Salcedo M, Vaquero J, Bañares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35(2):349-356
73. Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nuñez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc 2005;37(9):3968-3969
74. Tan CK, Sian Ho JM. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. Liver Transpl 2001;7(5):461-465
75. Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988;336(6195):176-179
76. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl 2002; 8(6):505-513
77. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004; 10(4):488-491
78. Petz W, Sonzogni A, Bertani A, et al. A cause of late graft dysfunction after pediatric liver transplantation: de novo autoimmune hepatitis. Transplant Proc 2002;34(5):1958-1959
79. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007;7(4):955-963
80. D'Antiga L, Dhawan A, Portmann B, et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002;73(1):80-84
81. Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and risk factors of de novo autoimmune hepatitis in livingdonor liver transplantation. Transplantation 2004;78(1):128-135
82. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001;126(3):535-539
83. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001;71(5):664-668
84. Riva S, Sonzogni A, Bravi M, et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl 2006;12(4):573-577
85. Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001;72(2):267-272
86. Hernandez HM, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001;32(2): 131-136